EMA - European Consumer Organisation (BEUC) bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 10 November 2025

Human medicines European public assessment report (EPAR): Jentadueto, linagliptin,metformin hydrochloride, Date of authorisation: 19/07/2012, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Cetrotide, cetrorelix, Date of authorisation: 12/04/1999, Revision: 30, Status: Authorised

List of medicines currently in PRIME scheme

PRIME: priority medicines

Human medicines European public assessment report (EPAR): Absimky, ustekinumab, Date of authorisation: 12/12/2024, Revision: 4, Status: Withdrawn

Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Blarcamesine Anavex, blarcamesine, Status: Opinion under re-examination

Human medicines European public assessment report (EPAR): Strimvelis, autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, Date of authorisation: 26/05/2016, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Qtern, saxagliptin,dapagliflozin, Date of authorisation: 15/07/2016, Revision: 14, Status: Authorised